Company and Competitor Profiling for Cytovance Biologics
Overview
Cytovance Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) headquartered in Oklahoma City, specializing in the development and cGMP manufacturing of biologics, including therapeutic proteins and antibodies through both mammalian and microbial systems. With over two decades of experience, the company excels in cell line development, process development, analytical solutions, and both clinical and commercial manufacturing, situating itself as a key partner in the biotech industry.
Services and Expertise
Cytovance Biologics offers a comprehensive suite of CDMO services, assisting in the commercialization of complex large molecules. Their capabilities include:
- Microbial Production: Encompassing strain development, along with batch and fed batch production.
- Mammalian Production: Covering cell line development and production of complex recombinant proteins in mammalian cultures.
- Commercialization Support: Comprehensive support in manufacturing process characterization, validation, and driving regulatory success.
The company also excels in working with various biologics such as recombinant proteins, enzymes, vaccines, and fusion proteins.
Strategic Collaborations
Cytovance has leveraged partnerships to enhance service offerings:
- Collaborated with PolyPeptide for integrated solutions in microbial and mammalian-expressed peptide development.
- Formed a strategic alliance with ExcellGene SA to foster innovation in large molecule biologics development and manufacturing.
Leadership
The executive leadership team at Cytovance Biologics includes:
- Ping Zhang, M.B.A., Chief Executive Officer: With comprehensive experience in the pharmaceutical industry, previously at Sanofi and Johnson & Johnson, Mr. Zhang emphasizes operational excellence.
- Jason Li, Ph.D., Chief Operating Officer: An academic and industry veteran with 35 years of experience in bioprocess design and development.
- Axel Schleyer, Ph.D., MBA, Chief Commercial Officer: With over 20 years in international clinical operations, Mr. Schleyer focuses on expanding the company’s commercial footprint.
Financial Insights
Cytovance Biologics has secured substantial capital for growth:
- Raised $44 million from investors including Great Point Partners and Presbyterian Health Foundation.
- Engaged in three funding rounds, accumulating $42.5 million in total capital.
Geographic and Industrial Reach
Strategically positioned in Oklahoma City, Cytovance delivers services to a global marketplace spanning North America, Europe, and the APAC region. The company plays a crucial role in the $7 billion Oklahoma biotechnology community, driving regional innovation and economic prosperity.
Commitment to Innovation and Quality
Cytovance Biologics prioritizes quality manufacturing processes aligned with regulatory standards, offering innovative solutions while maintaining a culture of responsiveness and reliability. Visit their official website for further details: [Cytovance Biologics](https://cytovance.com/).
Competitor Profiling
Notable Competitors
Cytovance Biologics engages with a competitive landscape that includes prominent industry entities.
- KBI Biopharma: A reputable biopharmaceutical contract service provider offering development to manufacturing, emphasizing personalized drug programs. Located in Durham, NC. [Website](http://www.kbibiopharma.com)
- Polpharma Biologics: Operates across Europe, focusing on biosimilar and novel biotherapeutics manufacturing. Based in Gdańsk, Poland. [Website](https://polpharmabiologics.com)
- Asymchem Laboratories: Founded in 1999, offering global R&D and manufacturing services with emphasis on green chemistry. Headquarters in Tianjin, China. [Website](https://www.asymchem.com)
Other Identified Competitors
- Pacific BioLabs
- Pace
- Abreos
- Advanced Microbial Services
- Boehringer Ingelheim
- Thermo Fisher Scientific
- Catalent Pharma
These competitors represent a diverse range of expertise and operational scale, influencing Cytovance Biologics' strategic decisions. The company aims to leverage its unique position, enhancing collaboration and differentiation within the market.
The industry dynamics experienced by Cytovance Biologics necessitate vigilant monitoring of competitor activities, allowing the company to seize growth opportunities and address potential challenges in the biotechnology and pharmaceuticals sectors.
